Oxurion Past Earnings Performance
Past criteria checks 0/6
Oxurion has been growing earnings at an average annual rate of 15.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 46.3% per year.
Key information
15.4%
Earnings growth rate
35.8%
EPS growth rate
| Biotechs Industry Growth | -3.6% |
| Revenue growth rate | -46.3% |
| Return on equity | n/a |
| Net Margin | -7,212.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
What Type Of Returns Would Oxurion's(EBR:OXUR) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Feb 01
How Is Oxurion's (EBR:OXUR) CEO Compensated?
Dec 09
Here's What We Learned About The CEO Pay At Oxurion NV (EBR:OXUR)
Aug 20Oxurion (EBR:OXUR) Share Prices Have Dropped 43% In The Last Year
Jul 17Revenue & Expenses BreakdownBeta
How Oxurion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -19 | 4 | 10 |
| 30 Sep 23 | 0 | -23 | 4 | 11 |
| 30 Jun 23 | 1 | -28 | 5 | 12 |
| 31 Mar 23 | 1 | -30 | 6 | 14 |
| 31 Dec 22 | 1 | -32 | 7 | 16 |
| 30 Sep 22 | 1 | -30 | 8 | 18 |
| 30 Jun 22 | 1 | -28 | 8 | 19 |
| 31 Mar 22 | 1 | -28 | 8 | 20 |
| 31 Dec 21 | 1 | -29 | 8 | 21 |
| 30 Sep 21 | 1 | -30 | 9 | 22 |
| 30 Jun 21 | 1 | -31 | 9 | 23 |
| 31 Mar 21 | 2 | -29 | 9 | 23 |
| 31 Dec 20 | 2 | -28 | 9 | 22 |
| 30 Sep 20 | 3 | -30 | 10 | 23 |
| 30 Jun 20 | 3 | -32 | 11 | 24 |
| 31 Mar 20 | 4 | -42 | 12 | 25 |
| 31 Dec 19 | 4 | -52 | 13 | 26 |
| 30 Sep 19 | 4 | -54 | 14 | 27 |
| 30 Jun 19 | 3 | -57 | 14 | 28 |
| 31 Mar 19 | 4 | -48 | 13 | 29 |
| 31 Dec 18 | 5 | -38 | 13 | 30 |
| 30 Sep 18 | 6 | -8 | 12 | 28 |
| 30 Jun 18 | 7 | 23 | 11 | 26 |
| 31 Mar 18 | 6 | 23 | 11 | 25 |
| 31 Dec 17 | 6 | 23 | 10 | 23 |
| 30 Sep 17 | 6 | -19 | 10 | 23 |
| 30 Jun 17 | 6 | -61 | 11 | 23 |
| 31 Mar 17 | 6 | -60 | 11 | 24 |
| 31 Dec 16 | 7 | -60 | 11 | 25 |
| 30 Sep 16 | 8 | -47 | 14 | 24 |
| 30 Jun 16 | 9 | -34 | 17 | 23 |
| 31 Mar 16 | 10 | -36 | 21 | 22 |
| 31 Dec 15 | 11 | -38 | 26 | 21 |
| 30 Sep 15 | 12 | -42 | 30 | 21 |
| 30 Jun 15 | 13 | -46 | 34 | 21 |
| 31 Mar 15 | 13 | -49 | 37 | 22 |
| 31 Dec 14 | 14 | -51 | 39 | 23 |
| 30 Sep 14 | 15 | -52 | 40 | 24 |
| 30 Jun 14 | 17 | -52 | 41 | 26 |
| 31 Mar 14 | 65 | -13 | 45 | 29 |
| 31 Dec 13 | 113 | 26 | 49 | 32 |
| 30 Sep 13 | 108 | 28 | 47 | 27 |
| 30 Jun 13 | 103 | 29 | 46 | 23 |
Quality Earnings: OXUR is currently unprofitable.
Growing Profit Margin: OXUR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OXUR is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare OXUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OXUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: OXUR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.